Loading clinical trials...

Optimizing Brain Excitability in Depression | Clinical Trials | Clareo Health

RECRUITINGNA

Optimizing Brain Excitability in Depression

Optimized Methods for Measuring Brain Excitability in Depression

NCT07242105•Stanford University

Summary

The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Men and women, ages 18 to 65
•Diagnosis of major depressive disorder, assessed through a Structured Clinical Interview for DSM-5 (SCID-5)
•In a current depressive episode, assessed through a Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (SCID-5)
•Moderate-to-severe depression as indicated by a score between 11-20 on the Quick Inventory of Depressive Symptoms (QIDS)
•Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales
•No current or history of neurological disorders
•No seizure disorder or risk of seizures
•Neurosurgical patients: Men and women ages 18-65 with medication-refractory epilepsy who are admitted for phase II intracranial monitoring to detect a seizure focus will be considered appropriate for this study. Participants must have the intellectual capacity to understand the consent process and agree to the study.

Exclusion Criteria

•Those with a contraindication for MRIs (e.g. implanted metal)
•History of head trauma with loss of consciousness
•History of seizures or on medications that reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium)
•Neurological or uncontrolled medical disease
•Any unstable medical condition
•Active substance abuse
•Diagnosis of psychotic or bipolar disorder
•A prior history of Electroconvulsive Therapy (ECT) failure
•History of suicide attempt in the past year
•Currently pregnant or breastfeeding
+1 more criteria

Locations (2)

University of Iowa

Iowa City, California, United States

Stanford University

Stanford, California, United States

Key Dates

Start Date

October 23, 2025

Primary Completion Date

August 30, 2029

Completion Date

November 30, 2029

Last Updated

February 10, 2026

Enrollment

145

ESTIMATED participants

Conditions

Major Depressive Disorder

Interventions

Active Single-Pulse TMS

DEVICE

Sham Single-Pulse TMS

DEVICE

TARGET-optimized TMS

DEVICE

Non-optimized (Open-Loop) TMS

DEVICE

EEG Recording

OTHER

Intracranial EEG (iEEG) Recording

OTHER

Contacts

Jade T Truong, BS

CONTACT

408-840-3313 kellerlab@stanford.edu

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Optimizing Brain Excitability in Depression

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use